Q4 2025 Mirum Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Mirum Pharmaceuticals Inc (MIRM) exceeded its net product sales guidance for 2025, achieving $521 million, driven by strong performance in both the US and international markets.
- The company anticipates significant growth in 2026, with projected net product sales between $630 to $650 million.
- Mirum Pharmaceuticals Inc (MIRM) advanced its pipeline with key clinical and regulatory milestones, including the approval of etexlate for CTX and a tablet formulation of Livmarli.
- The company expanded its pipeline with the addition of the phase 3 Brilovat program for chronic hepatitis Delta virus, enhancing its portfolio in rare diseases.
- Mirum Pharmaceuticals Inc (MIRM) achieved a positive cash flow from operations in 2025 and ended the year with a strong cash position of $391 million.
- The company expects an increase in R&D expenses in 2026, primarily due to investments in the Berlovitard clinical program and manufacturing scale-up.
- Despite strong sales growth, the guidance for 2026 implies a slower growth rate of 21 to 25% compared to the 55% growth in 2025.
- The market for Velixabat in PSC is uncertain, with potential variability in patient response due to episodic pruritus.
- Mirum Pharmaceuticals Inc (MIRM) faces competitive pressures in the hepatitis Delta virus market, with other treatments potentially entering the US market.
- The company must navigate complex safety database requirements for Velixabat's FDA submission, which could impact the timing of regulatory approvals.
Good afternoon and welcome to Mirrem Pharmaceuticals, fourth quarter and full year 2025 conference call.
My name is Elliot and I'll be your operator today.
All lines are currently in listen learning mode, and there'll be an opportunity for Q&A after management's prepared remarks.
And I'd like to hand the conference over to Andrew McKibben, SVP of strategic finance and Investor relations. Please go ahead.
Thank you, Elliott, and good afternoon, everyone. I'd like to welcome you to Miriam Pharmaceuticals 4th quarter and full year 2025 conference call. I'm joined today by our Chief Executive Officer Chris Peetz, our Chief Medical Officer, Joanne Kwan, and Eric Berkel, our Chief Financial Officer. Peter Radovich, our President and Chief Operating Officer, is unable to join us today as he's attending an international commercial event.
Earlier this afternoon, Miriam issued a press release reporting our fourth quarter and full year 2025 financial results. Copies
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
